What is Tasly Pharmaceutical Group Co Net Margin %?
Tasly Pharmaceutical Group CoSHSE:600535 -2.50%78 Net Margin % is 17.10% as of Mar. 2026, which is 100% above its 10-year median of 8.57. GuruFocus rates SHSE:600535 with a GF Score™ of 78/100 and a GF Value™ of ¥14.99 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 956 Drug Manufacturers companies, Tasly Pharmaceutical Group Co ranks better than 75.84% on this metric.
The historical rank and industry rank for Tasly Pharmaceutical Group Co's Net Margin % or its related term are showing as below:
SHSE:600535'
s Net Margin % Range Over the Past 10 Years
Min: -3.06 Med: 8.57 Max: 29.66
Current: 13.91
SHSE:600535's Net Margin % is ranked better than 75.84% of 956
companies
in the Drug Manufacturers industry
Industry Median: 5.56
vs SHSE:600535: 13.91
Tasly Pharmaceutical Group Co (SHSE:600535) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Tasly Pharmaceutical Group Co Net Margin % Related Terms
Tasly Pharmaceutical Group Co Net Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Tasly Pharmaceutical Group Co's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tasly Pharmaceutical Group Co Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Tasly Pharmaceutical Group Co's Net Margin % distribution charts can be found below:
* The bar in red indicates where Tasly Pharmaceutical Group Co's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tasly Pharmaceutical Group Co (SHSE:600535) has a Net Margin % of 17.10% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Tasly Pharmaceutical Group Co and its competitors. This is 100% above median its historical median of 8.57. According to the industry distribution chart, Tasly Pharmaceutical Group Co ranks #231 out of 956 companies in the Drug Manufacturers industry, placing it in the top 24.2%.
Is Tasly Pharmaceutical Group Co's Net Margin % too high?
Tasly Pharmaceutical Group Co's current Net Margin % of 17.10% is 100% above median its 10-year median of 8.57. The Drug Manufacturers industry median Net Margin % is 5.56. Tasly Pharmaceutical Group Co's value of 17.10% is 207.6% above this industry median. Based on the distribution chart, Tasly Pharmaceutical Group Co ranks #231 out of 956 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Tasly Pharmaceutical Group Co has a GF Score™ of 78/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Tasly Pharmaceutical Group Co's Net Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Tasly Pharmaceutical Group Co ranks #231 out of 956 companies for Net Margin %. This places Tasly Pharmaceutical Group Co in the top 24% of its industry — outperforming the majority of peers. The industry median Net Margin % is 5.56. Tasly Pharmaceutical Group Co's value of 17.10% is 207.6% above this benchmark. While the company's 10-year median is 8.57 vs. the industry median of 5.56, Tasly Pharmaceutical Group Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.56, based on 956 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tasly Pharmaceutical Group Co's current Net Margin % of 17.10% is 207.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Tasly Pharmaceutical Group Co and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tasly Pharmaceutical Group Co's current Net Margin % is 17.10%, which is 100% above median its own 10-year median of 8.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tasly Pharmaceutical Group Co stock overvalued right now?
Based on GuruFocus' analysis, Tasly Pharmaceutical Group Co (SHSE:600535) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥14.99, compared to a current price of ¥13.24 — trading 11.7% below its estimated fair value. The current Net Margin % is 17.10%, which is 100% above median its 10-year median of 8.57 and 207.6% above the Drug Manufacturers industry median of 5.56. Tasly Pharmaceutical Group Co's overall GF Score™ is 78/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Tasly Pharmaceutical Group Co (SHSE:600535), the current Net Margin % is 17.10% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tasly Pharmaceutical Group Co (SHSE:600535) Overvalued in 2026?
Based on GuruFocus' analysis, Tasly Pharmaceutical Group Co stock appears to be undervalued.
The current stock price of ¥13.24 is trading 11.7% below its estimated GF Value™ of ¥14.99.
GuruFocus considers Tasly Pharmaceutical Group Co to be Modestly Undervalued.
Key valuation signals for SHSE:600535:
Net Margin %: 17.10% (100% above median its 10-year median of 8.57)
GF Value™: ¥14.99 vs. price of ¥13.24 (11.7% below fair value)
Industry Position: 207.6% above the Drug Manufacturers median (#231 of 956)
No single metric tells the full story. See the SHSE:600535 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tasly Pharmaceutical Group Co Business Description
Tasly Pharmaceutical Group Co Ltd is a China-based company engaged in the manufacturing and distribution of pharmaceutical products. Its herbal medicines include Tasly Cerebral Care Granules and Tasly ICP. Its chemical medicines comprise of Ketotifen Fumarate Tablets, Thiamphenicol Capsules, Glucurolactone Tablets and Sulpiride Tablets. Some of the other products offered by the company include PharmceuticalSubstances & API, HerbalExtract, and Concentrated Herbal Granules.
78GF Score
Get the complete analysis for SHSE:600535
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600535 has been successfully added to your 
